La Roche-Posay is positioning pigmentation as both a dermatological and emotional health issue. Its new Mela B3 Double Dose Discoloration Treatment contains 1% Melasyl alongside Proxylane to simultaneously target discoloration and visible signs of aging across the face, neck, décolleté and hands. L'Oreal
L'Oréal Paris is bringing the company's patented Melasyl technology to the mass market through its new Revitalift Melasyl Dark Spot Creamy-Serum, while La Roche-Posay is expanding its dermatologist-led Mela B3 franchise with a higher-potency treatment that pairs pigment correction with anti-aging benefits.
Both launches are powered by Melasyl (INCI: 2-mercapto nicotinoyl glycine), L'Oréal Groupe's multi-patented pigment-management molecule developed after nearly two decades of research and the screening of more than 100,000 candidate molecules. Protected by 23 patents worldwide and recognized as one of Time's Best Inventions of 2025, the active represents a shift away from traditional pigment inhibitors by targeting excess pigmentation at an earlier stage in melanin formation.
According to L'Oréal, Melasyl works by intercepting reactive melanin precursors—including dopaquinone, DHI and DHICA—before they accumulate into localized areas of excess pigmentation. Rather than blocking melanin production altogether, the company says the molecule helps deactivate these intermediates to manage hyperpigmentation while preserving the skin's normal pigmentation processes, an approach intended to improve skin tone uniformity without disrupting natural skin color. The technology has been clinically validated across diverse skin phototypes for concerns including melasma, post-inflammatory hyperpigmentation, age spots and sun-induced discoloration.
The launches illustrate how brands are increasingly differentiating themselves by tailoring the same breakthrough technology to distinct consumer segments and positioning strategies.
For L'Oréal Paris, the emphasis is democratizing advanced pigment science. The Revitalift launch introduces Melasyl into the brand's flagship anti-aging franchise at a mass-market price point of $29.99, combining the ingredient with niacinamide and Vitamin Cg in a hybrid creamy-serum format. The product also features a twist-and-pump delivery system designed to protect formula integrity while dispensing a precise dose, signaling that packaging innovation is becoming part of the efficacy story alongside formulation.
La Roche-Posay, meanwhile, is positioning pigmentation as both a dermatological and emotional health issue. Its new Mela B3 Double Dose Discoloration Treatment contains 1% Melasyl alongside proxylane to simultaneously target discoloration and visible signs of aging across the face, neck, décolleté and hands. Rather than focusing solely on clinical performance, the brand is also highlighting the psychosocial burden of pigmentary disorders. Survey data from more than 23,000 people found that many individuals with conditions such as melasma, post-inflammatory hyperpigmentation and solar lentigo reported experiencing stigma in everyday life, from workplace discrimination to negative social interactions.
The company is extending that message through a renewed partnership with actress Keke Palmer, pairing product launches with education around skin tone equity and broader awareness of hyperpigmentation.
For beauty industry stakeholders, the dual launches underscore several broader market shifts: pigment correction is evolving beyond simple "dark spot" claims into comprehensive skin tone management; anti-aging and pigmentation are increasingly being addressed together in multifunctional products; and brands are increasingly leveraging proprietary, mechanism-driven ingredients supported by extensive patent portfolios and inclusive clinical validation to differentiate in an increasingly competitive brightening category.
As melasma and persistent hyperpigmentation continue to gain attention among consumers, brands are increasingly treating pigmentation not as a niche concern, but as a core pillar of premium and mass skin care innovation.
